Inflammatory Bowel Disease (IBD) & Drugs/Treatments

What are the individual success rates in the treatment of Inflammatory Bowel Disease (IBD)?

The individual treatment success rates are only 20 to 30% (1).

How long do patients with IBD usually need to be treated?

Patients suffering from Inflammatory Bowel Disease (IBD) mostly require lifelong treatment (15).

Why Do Some Inflammatory Bowel Disease (IBD) Patients Not Respond to Treatment or Lose Their Treatment Response Over Time?

Many of these therapies are administered parenterally and have been associated with adverse events such as serious infections or malignancy. This highlights a significant unmet medical need to minimize symptoms and promote GI healing. Although these treatments have generally benefited patients, there are significant challenges:

• Approximately 30% of patients do not respond to induction (initial) therapy.


• Up to 50% of patients lose response to treatment over a year (2).

What medications are currently commonly used to treat IBD?

At present, the commonly used drugs for the treatment of Inflammatory Bowel Disease (IBD) include immunosuppressive drugs , biological agents (infliximab and tacrolimus), and antibiotics (16).

What treatment is 5-ASA often used for?

5-aminosalicylic acid (5-ASA) is widely used to treat IBD due to its good clinical efficacy (19).

Which monoclonal antibodies targeting cytokines are currently used to treat inflammatory bowel disease (IBD), and why are these therapies so expensive?

Monoclonal cytokines such as Anti-Tumor Necrosis Factor alfa (TNF-alfa) antibodies / Tumor Necrosis Factor alfa (TNF-alfa) inhibitors and Anti-Interleukin-6 (IL-6) antibodies can also treat Inflammatory Bowel Disease (IBD), but the high production cost of this method makes it unacceptable for some patients (17).

How Do Cytokine-Blocking Therapies, Such as TNF Inhibitors, Treat Inflammatory Bowel Disease (IBD)?

Neutralizing cytokines is a recognized treatment for IBD (7). Agents that block cytokines, like TNF, suppress the immune system. These agents are clinically effective for patients with IBD (8).

How Do Anti-TNF-Alpha Inhibitors Treat Crohn’s Disease and Ulcerative Colitis?

Anti-tumor necrosis factor (TNF-alfa) have been the mainstay therapy for Crohn’s disease and ulcerative colitis (UC) for decades .Selecting and sequencing Inflammatory Bowel Disease (IBD) therapies remains a clinical challenge. Disease phenotype, severity of symptoms, patient comorbidities, and prior drug exposure should be considered when considering therapy options. Anti-TNF remains a time-tested option that is effective in both UC and CD (5).

Does Long-Term Immunosuppressive Therapy Increase Cancer Risk in Patients with Inflammatory Bowel Disease (IBD)?

Inflammatory bowel disease (IBD) is a chronic illness requiring optimal long-term medical therapy to enhance quality of life and reduce disease-related complications. Fine-tuning therapy is crucial to prevent treatment-related issues like infections and cancer. The relationship between immunosuppression, chronic inflammation, and cancer development in IBD patients is unclear, impacting physicians' confidence in prescribing and patients' confidence in medication adherence (9, 10, 11, 12, 13).

Why Are New Treatments Needed for Inflammatory Bowel Disease (IBD)?

Despite significant advancements in the treatment of inflammatory bowel disease (IBD), a substantial percentage of patients with Crohn's disease (CD) and ulcerative colitis (UC) still require effective and safe therapeutic options (3). Several drugs seem to alleviate symptoms associated with Inflammatory Bowel Disease (IBD); however, maintaining long-term remission remains a challenge. Both clinicians and patients are in urgent need of new therapeutic strategies (4).

What Are the Emerging Therapeutic Targets for Inflammatory Bowel Disease (IBD)?

With growing need for highly effective therapy, various therapeutic targets have been introduced including anti-integrins, anti-interleukin (IL) 12/23, selective anti-IL23, Janus Kinase (JAK) inhibitors, sphingosine-1-phosphate (S1P) receptor modulators, and mRNA-124 splicing agent (5).

How Have Anti-Integrins and S1P Receptor Modulators Expanded IBD Treatment Options?

The Inflammatory Bowel Disease (IBD) treatment option is beyond biologic agents widened with recent approvals of anti-integrins (e.g., Vedolizumab (L04AG05) and natalizumab) and sphingosine-1-phosphate (S1P) receptor modulators (e.g., ozanimod) (6).

Can psychological interventions and complementary therapies improve outcomes alongside conventional treatment for inflammatory bowel disease (IBD)?

The widespread use and potential impact of complementary and alternative medicine and the positive placebo effect (in clinical trials) indicate that exploring other psychological interventions may be an essential therapeutic complement to the conventional therapeutic approach in Inflammatory Bowel Disease (IBD) (18).

Do Fecal Microbiota Transplantation, Diet, Naltrexone, and Cannabis Help Treat Inflammatory Bowel Disease (IBD)?

Current treatments for Inflammatory Bowel Disease (IBD) are not universally effective and have the potential for adverse events. The majority of currently available therapies target the mucosal immune response, and these therapies are hampered by incomplete efficacy and significant adverse events. Consequently, patients with Crohn’s disease (CD) and ulcerative colitis (UC) often seek complementary and alternative therapies including Fecal Microbiota Transplantation (FMT), dietary manipulation, naltrexone, and cannabis. Despite the popularity of these treatments, the evidence for benefit is limited (14).

References

(1) Alsoud et al. 2021 Lancet Gastroenterol Hepatol 6(7): 589-595
(2) Pippis et al. 2021 Inflamm Bowel Dis 27(10): 1674
(3) Solitano et al. 2021 Expert Opinion on Investigational Drugs 30(10): 1037-1046
(4) Feng et al. 2023 Biomed Pharmacother 158: 114174
(5) Wong & Cross 2022 Expert Opinion on Emerging Drugs 27(4): 369-377
(6) Choden et al. 2022 Gastroenterol Hepatol (N. Y.) 18: 265-271
(7) Zahirović & Berlec 2022 Microb Cell Fact 21: 143
(8) Zhang et al. 2022h Cell Communication and Signaling 20: 64
(9) Johnson et al. 2010 J Manag Care Pharm. 16: 616–628
(10) Lemaitre et al. 2017 JAMA 318: 1679-1686
(11) Kirchgesner et al. 2018 Gastroenterology 155: 337-346
(12) Bewtra et al. 2020 Clinical Gastroenterology and Hepatology 18: 406-414
(13) Khan et al. 2020a Inflamm Bowel Dis. 26: 462-468
(14) Chande et al. 2020 Inflamm Bowel Dis 26: 843-851
(15) Kempski et al. 2017
(16) Wang et al. 2016g Cochrane Database of Systematic Reviews 5: CD000544
(17) Sandborn et al. 2014 Gastroenterology 146(1): 85–95
(18) Bonaz & Bernstein 2013 Gastroenterology 144(1): 36-49
(19) Rousseaux et al. 2005 Journal of Experimental Medicine 201(8): 1205–1215

see also:
Brain-Gut-Microbiome-Axis / Gut-Brain Axis & Inflammatory Bowel Disease (IBD)
Cancer / Tumors & Inflammation / Inflammatory diseases
Fecal Microbiota Transplantation (FMT) & Crohn’s Disease (CD)
Fecal Microbiota Transplantation (FMT) & Ulcerative Colitis (UC)
Ulcerative colitis (UC) & Drugs/Treatments